SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
ALNYLAM PHARMACEUTICALS INC
(NQNM:ALNY Last Sale: 136.63 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (ALNY : $136.63)
$15,449,079 million Market Cap at Market Close, July 1, 2022
Employs 173.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
300 Third Street Research Report Earnings Snapshot - Last 11/05/18
3rd Floor Fact Sheet
Cambridge, MA 02142 Financial Statements
Phone: (617) 551-8200 Peer Comparison
Annual Reports

John K. Clarke, Co-Founder/Chmn., Phillip Sharp, Co-Founder, John M. Maraganore, Pres./CEO, Barry E. Greene, COO, Patricia L. Allen, CFO
Focus is RNAi technology, which involves preventing genes from producing certain proteins that cause disease. Has license with both ROCHE and NOVARTIS, which holds 13.4%, and extended thru 2010 on July 19, 2009. In 2005 Novartis paid $56.8 million for 4.2 million shares at $11.11, and specified potential future payments of $700 million, plus royalties, based on performance. Under $1 billion agreement of July 9, 2007 ROCHE paid $331 million for 1.975 million shares at $21.50, and acquired the Alnylam RNAi research center in Kulmbach, Germany, and ALNY agreed to pay $26.5 million to ISIS PHARMACEUTICALS (ISIS) under their strategic relationship. Launched a joint venture with ISIS, Regulus Therapeutics LLC, to develop microRNA therapies, September 7, 2007. IPO at $6 May 27, 2004. Raised $30 million, selling 5 million shares, 26% of the outstanding. Lead Manager: Banc of America. Secondary sold 5.1 million common shares at $13 January 31, 2006. Sanofi bought 12% for $700 million as part of an expanded alliance to develop treatments for rare genetic diseases January 13, 2014.
Historical Charts    Technical Analysis
No Historical Data available for ALNY

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common ALNY $136.63 $136.63 0 .0 $129.02 $136.77 892,342 $129.02 $136.77 113,072,381
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126
Common Stock #############

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex